Loading
Cell Therapy / No Option Disease · Journal article
Regenerative Therapy · July 29, 2026
A consensus or society position rather than new primary data.
This structured narrative review synthesizes evidence linking host-state biomarkers—including inflammatory, nutritional, renal, metabolic, lipid, coagulation, infection, dialysis, frailty, smoking, etiology, and perfusion markers—to CLTI outcomes in the context of cell therapy trials. Current evidence supports prognostic risk stratification but not yet validated prediction of differential treatment response; the authors propose a trial-design framework using provisional favorable, intermediate, and unfavorable host-state profiles for prospective validation, with stratified randomization and prespecified interaction analyses, while cautioning that these are hypothesis-generating strata, not clinical eligibility criteria.
Structured narrative review. Patients with chronic limb-threatening ischemia (CLTI), particularly no-option and poor-option disease; review synthesizes evidence on host-state biomarkers and clinical factors associated with cell therapy trial outcomes..
Approximately 20%–30% of CLTI patients are classified as 'no-option' (unsuitable for revascularization or who have failed it) Recent series report 1-year major-amputation rates of 10%–40% and mortality rates of 20%–25%, with 5-year mortality approaching 50%–60% Inflammatory, nutritional, renal, metabolic, lipid, coagulation-related, infection, dialysis, frailty, smoking, etiology, and perfusion-related variables may shape the regenerative microenvironment and contribute to heterogeneity in cell therapy trial outcomes
Recent series report 1-year major-amputation rates of 10%–40% and mortality rates of 20%–25%, with 5-year mortality approaching 50%–60%
Clinicians and cell therapy trial designers should use the proposed host-state stratification framework to improve prognostic enrichment and baseline risk adjustment in CLTI trials, but must recognize that listed biomarkers and clinical factors are currently hypothesis-generating candidate variables requiring prospective validation, not validated treatment-selection criteria or gatekeeping thresholds. Standardized biomarker assays, harmonized endpoints, transparent reporting of cell products, and randomized testing of host-state × treatment interactions are needed to advance precision regenera
A structured narrative review synthesizing evidence on host-state biomarkers and clinical factors for CLTI cell therapy trial design, proposing a conceptual framework for prognostic stratification rather than reporting new primary efficacy data.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and cell therapy trial designers should use the proposed host-state stratification framework to improve prognostic enrichment and baseline risk adjustment in CLTI trials, but must recognize that listed biomarkers and clinical factors are currently hypothesis-generating candidate variables requiring prospective validation, not validated treatment-selection criteria or gatekeeping thresholds. Standardized biomarker assays, harmonized endpoints, transparent reporting of cell products, and randomized testing of host-state × treatment interactions are needed to advance precision regenera
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. Chronic limb-threatening ischemia (CLTI) is a severe manifestation of peripheral arterial disease associated with high risks of amputation and mortality. Trials of cell-based therapies in patients unsuitable for revascularization ("no-option" or "poor-option" CLTI) have produced inconsistent results, underscoring the need for improved prognostic enrichment, baseline risk balancing, and protocol-defined stratification.Main body. This structured narrative review synthesizes evidence linking host-state markers-including laboratory biomarkers, clinical host-state factors, and physiologic/perfusion indices-to clinically meaningful CLTI outcomes. Inflammatory, nutritional, renal, metabolic, lipid, coagulation-related, infection, dialysis, frailty, smoking, etiology, and perfusion-related variables may shape the regenerative microenvironment and contribute to heterogeneity in cell therapy trial outcomes. However, current evidence primarily supports prognostic risk stratification rather than validated prediction of differential treatment response. We therefore interpret treated-cohort associations and post hoc subgroup observations as hypothesis-generating candidate variables for prospective host-state × treatment interaction testing, not as validated predictive biomarkers. We propose a conceptual trial-design framework: first, confirm no-option or poor-option CLTI through multidisciplinary review, guideline-aligned assessment, objective hemodynamic testing, vascular imaging, and multidomain assessment; second, provisionally categorize patients into favorable, intermediate, and unfavorable host-state profiles using approximate prognostic ranges for prospective validation rather than clinical eligibility cutoffs, treatment-selection rules, or gatekeeping thresholds; third, ensure clinically necessary stabilization before eligibility confirmation and treat any run-in or post-randomization optimization strategy only as an optional, secondary, protocol-justified design component; and fourth, apply stratified randomization, covariate adjustment, blinded outcome adjudication, and prespecified host-state × treatment interaction analyses.Conclusions. Integrating host-state biomarkers and clinical factors into CLTI cell therapy trial design may support prognostic enrichment, stratified enrollment, baseline risk adjustment, and hypothesis-driven evaluation of treatment-effect heterogeneity. The proposed profiles are hypothesis-generating trial-design strata, not validated clinical eligibility criteria, treatment-selection rules, or biomarker-based gatekeeping thresholds. Prospective validation will require standardized biomarker assays, harmonized endpoints, transparent reporting of cell products and concomitant care, and randomized testing of host-state × treatment interactions to advance precision regenerative medicine in this setting.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.